Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | ACLY | P53396 | 2/20 | 0.51 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.51 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.51 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.51 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | BRD1 | O95696 | 1/20 | 0.49 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.49 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.45 |
| ▸ | CTSG | P08311 | 1/20 | 0.45 |
| ▸ | CMA1 | P23946 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28685956 | 0.85 | IDO1 (0.48) | PGRRXFP1ACLYKAT6AGLO1 | |
| SCHEMBL11777272 | 0.84 | L3MBTL1 (0.49) | L3MBTL1EGFRTNNI3K | |
| SCHEMBL420253 | 0.82 | PGR (0.54) | PGRRXFP1ACLYKAT6AGLO1 | |
| SCHEMBL17818389 | 0.82 | CA12 (0.61) | MAPTL3MBTL1EGFRTNNI3K | |
| SCHEMBL4615617 | 0.81 | PGR (0.50) | PGRRXFP1ACLYKAT6AGLO1 | |
| SCHEMBL16000124 | 0.81 | NR3C1 (0.52) | PGRRXFP1ACLYKAT6AGLO1 | |
| SCHEMBL13900229 | 0.81 | MAPT (0.63) | PGRRXFP1ACLYKAT6AGLO1 | |
| SCHEMBL6027529 | 0.81 | GLO1 (0.51) | PGRRXFP1ACLYKAT6AGLO1 | |
| SCHEMBL2242660 | 0.80 | L3MBTL1 (0.61) | MAPTL3MBTL1EGFRTNNI3K | |
| SCHEMBL17127741 | 0.80 | KAT6A (0.53) | PGRRXFP1ACLYKAT6AGLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116082201-B | Synthetic method of chloro-bicyclo [1.1.1] pentylamine derivative | 浙江工业大学 | 2024-06-21 | — | — | CN | disclosed |
| CN-116082201-A | Synthetic method of chloro-bicyclo [1.1.1] pentylamine derivative | 浙江工业大学 | 2023-05-09 | — | — | CN | disclosed |
| WO-2023077057-A1 | SMALL-MOLECULAR INHIBITORS FOR THE BETA-CATENIN/ B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20220235043-A1 | SUBSTITUTED SULFONAMIDE PYRROLOPYRIDINES AS JAK INHIBITORS | ACLARIS THERAPEUTICS, INC. | 2022-07-28 | — | — | US | disclosed |
| WO-2021022178-A1 | SUBSTITUTED SULFONAMIDE PYRROLOPYRIDINES AS JAK INHIBITORS | ACLARIS THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| US-20170144971-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20160137667-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC. (US) | 2016-05-19 | — | — | US | disclosed |
| US-9296736-B2 | Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer | AMGEN INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20160046597-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER (US) | 2016-02-18 | — | — | US | disclosed |
| US-9199959-B2 | HIV replication inhibitor | SHIONOGI & CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-8202863-B2 | 2-Phenyl-pyrimidine-5-carboxylic acid benzylamide; to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease | AVENTIS PHARMACEUTICALS INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20110319378-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20080227782-A1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2008-09-18 | — | — | US | disclosed |
| EP-1937652-A1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1633714-B1 | 2-AMINO-PYRIDINE DERIVATIVES AS BETA-2 ADRENORECEPTOR AGONISTS | PFIZER LTD (GB) | 2008-01-23 | — | — | EP | disclosed |
| WO-2007041634-A1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| EP-1270577-B1 | FUROISOQUINOLINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2006-12-06 | — | — | EP | disclosed |
| US-6924292-B2 | Furoisoquinoline derivatives, process for producing the same and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-02 | — | — | US | disclosed |
| US-20040092582-A1 | Furoisoquinoline derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-13 | — | — | US | disclosed |
| EP-1270577-A1 | FUROISOQUINOLINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227782-A1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | HRH2, HRH1, LTC4S | PGR 24/4885RXFP1 379/4885ACLY 1067/4885 |
| US-20220235043-A1 | SUBSTITUTED SULFONAMIDE PYRROLOPYRIDINES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | PGR 3243/4885RXFP1 1442/4885ACLY 2862/4885 |
| US-20110319378-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | MDM2, TP53, CDKN1A | PGR 1695/4885RXFP1 4402/4885ACLY 3874/4885 |
| US-20160046597-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | PGR 1471/4885RXFP1 157/4885ACLY 3459/4885 |
| US-20160137667-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | PGR 1695/4885RXFP1 4402/4885ACLY 3874/4885 |
| US-20040092582-A1 | Furoisoquinoline derivatives, process for producing the same and use thereof | PDE3B, PDE5A, PDE3A | PGR 4409/4885RXFP1 146/4885ACLY 3145/4885 |
| US-20170144971-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | PGR 1695/4885RXFP1 4402/4885ACLY 3874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.